Search | IOVS | ARVO Journals

Showing 1 – 20 of 37

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

UKIDS study: Quantitative multi-organ MRI imaging stratifies diabetics with cardiac & abdominal phenotypes specific to proliferative diabetic retinopathy (PDR) & clinically significant diabetic macular edema (CSME, DME)

Durreshahwar Hashmi; Charlie Diamond; Kim Chapman; Christopher Holmes; Isabel De La Paz; Tiffany Wilkinson; Helena Thomaides Brears; Rajarshi Banerjee; Ian Yeung; Robin Hamilton

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3194.

ARVO Annual Meeting Abstract June 2024

Real-world outcomes of faricimab injections in treatment-naïve neovascular age-related macular degeneration (nAMD) patients: The Moorfields Experience

Sing Yue Sim; Luke Nicholson; Praveen J Patel; Bhairavi Bhatia; Evangelia Chalkiadaki; Georgios Koutsocheras; Senthil Selvam; Sobha Sivaprasad; Bishwanath Pal; Pearse Andrew Keane; Robin Hamilton

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):246.

ARVO Annual Meeting Abstract June 2024

Intraocular Inflammation Associated with Faricimab Therapy: The Moorfields Experience.

Andrea Montesel; Sagnik Sen; Ella Preston; Sing Yue Sim; Praveen J Patel; Josef Christian Huemer; Robin Hamilton; Luke Nicholson; William Tucker; Ioannis Papasavvas; Ian Yeung

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):245.

ARVO Annual Meeting Abstract June 2024

Comparative analysis of anatomical and visual parameters in treatment-resistant neovascular age related macular degeneration (nAMD) patients pre- and post-switch to faricimab: A Moorfields Analysis

Georgios Koutsocheras; Evangelia Chalkiadaki; Sing Yue Sim; Senthil Selvam; Bhairavi Bhatia; Sobha Sivaprasad; Bishwanath Pal; Pearse Andrew Keane; Luke Nicholson; Robin Hamilton; Praveen J Patel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4316.

ARVO Annual Meeting Abstract June 2024

Real-world outcomes of a Ranibizumab biosimilar product (Ongavia) in neovascular age related macular degeneration (nAMD) patients switched from a reference Ranibizumab product (Lucentis)

Evangelia Chalkiadaki; Abu Karim; Ian Yeung; Georgios Koutsocheras; Sing Yue Sim; Bishwanath Pal; Sobha Sivaprasad; Luke Nicholson; Robin Hamilton

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1944.

ARVO Annual Meeting Abstract June 2024

Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-related Macular Degeneration: A Moorfields Analysis

Bhairavi Bhatia; Sing Yue Sim; Evangelia Chalkiadaki; Georgios Koutsocheras; Luke Nicholson; Senthil Sevlam; Pearse Andrew Keane; Bishwanath Pal; Sobha Sivaprasad; Robin Hamilton; Praveen J Patel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4902.

ARVO Annual Meeting Abstract June 2023

Five-year outcomes of ranibizumab for myopic choroidal neovascular membrane stratified by age of onset

Priyanka Sanghi; Filipa Rodrigues; Binu John; Karina Spiess; Judytna Jankowska-Szmul; Dhakshi Muhundhakumar; Theodora Gkika; Rola Baabbad; Simona Degli Esposti; Robin Hamilton; Sobha Sivaprasad; Bishwanath Pal; Luke Nicholson

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1557.

ARVO Annual Meeting Abstract June 2023

Anatomical and visual outcomes of patients with active neovascular age related macular degeneration(nAMD) requiring monthly anti-VEGF treatment following switch to faricimab

Sing Yue Sim; Evangelia Chalkiadaki; Georgios Koutsocheras; Robin Hamilton; Luke Nicholson; Bishwanath Pal; Praveen J Patel; Pearse Keane; Sobha Sivaprasad

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2206.

ARVO Annual Meeting Abstract June 2023

Intravitreal Aflibercept for Diabetic Macular Oedema in Real-world; 5-Year Visual Acuity and Anatomical Outcomes

Marko Lukic; Robin Hamilton; Ranjan Rajendram

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2646.

ARVO Annual Meeting Abstract June 2020

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Rishi P Singh; Robin Hamilton; Jeffrey S Heier; Carl Regillo; Mark C Gillies; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1158.

ARVO Annual Meeting Abstract July 2019

Individualizing therapy for neovascular age-related macular degeneration with aflibercept (the VITAL study): A two year prospective, interventional single-centre trial

Simona Degli Esposti; Maria K Gemenetzi; Maria Eleftheriadou; Hari Jayaram; Bishwanath Pal; Niaz Islam; Peter Addison; Robin Hamilton; Praveen Patel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):85.

ARVO Annual Meeting Abstract July 2019

A Retrospective Study of Real World Data for stable wet AMD treatment with aflibercept

Maria K Gemenetzi; Praveen Patel; Shweta Anand; Marko Lukic; Simona Degli Esposti; Pearse Andrew Keane; Ella Preston; Robin Hamilton

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1162.

ARVO Annual Meeting Abstract July 2019

Treat-and-extend Aflibercept in the treatment of macular edema due to CRVO: 18 months results of real life data

Theodora Gkika; Ella Preston; Robin Hamilton; Peter Addison; Bishwanath Pal

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2575.

ARVO Annual Meeting Abstract July 2019

Intravitreal Aflibercept for Diabetic Macular Oedema in Real-world; 24 Month Visual Acuity and Anatomical Outcomes

Marko Lukic; Praveen Patel; Robin Hamilton; Ranjan Rajendram

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3652.

ARVO Annual Meeting Abstract July 2019

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Rishi P Singh; Charles Clifton Wykoff; Ramin Tadayoni; Yuichiro Ogura; Adrian H C Koh; Frank G Holz; Robin Hamilton; David Tanzer; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5194.

ARVO Annual Meeting Abstract July 2018

Twelve Months Outcomes in Switched Patients Treated with Intravitreal Aflibercept for Diabetic Macular Oedema

Marko Lukic; Zaid Shalchi; Gwyn Williams; Praveen Patel; Robin Hamilton; Ranjan Rajendram

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3600.

ARVO Annual Meeting Abstract July 2018

Comparison of anatomical and functional outcomes of treatment with bevacizumab and ranibizumab injections in eyes with myopic choroidal neovascularization (mCNV)

Malgorzata Woronkowicz; Susan Lightman; Robin Hamilton; Sophia Zagora; Oren Tomkins-Netzer

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4745.

ARVO Annual Meeting Abstract July 2018

Recurrence of Choroidal Neovascularization after cataract operation in Age Related Macular Degeneration

Robin D Hamilton; Anastasia Tasiopoulou; Adam Mapani; Panagiotis Vasilopoulos; Gabriella Preston

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1468.

ARVO Annual Meeting Abstract June 2017

Characterizing posterior capsule rupture during cataract surgery in eyes with prior intravitreal injection

Zaid Shalchi; Robin Hamilton

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):790.

ARVO Annual Meeting Abstract June 2017

Three-Year Real World Outcomes of Aflibercept Treatment of Treatment-naïve Patients with Neovascular Age-related Macular Degeneration

Maria Eleftheriadou; Maria K Gemenetzi; Sobha Sivaprasad; Philip G Hykin; Robin Hamilton; Adnan Tufail; Praveen J Patel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):874.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

UKIDS study: Quantitative multi-organ MRI imaging stratifies diabetics with cardiac & abdominal phenotypes specific to proliferative diabetic retinopathy (PDR) & clinically significant diabetic macular edema (CSME, DME)

Real-world outcomes of faricimab injections in treatment-naïve neovascular age-related macular degeneration (nAMD) patients: The Moorfields Experience

Intraocular Inflammation Associated with Faricimab Therapy: The Moorfields Experience.

Comparative analysis of anatomical and visual parameters in treatment-resistant neovascular age related macular degeneration (nAMD) patients pre- and post-switch to faricimab: A Moorfields Analysis

Real-world outcomes of a Ranibizumab biosimilar product (Ongavia) in neovascular age related macular degeneration (nAMD) patients switched from a reference Ranibizumab product (Lucentis)

Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-related Macular Degeneration: A Moorfields Analysis

Five-year outcomes of ranibizumab for myopic choroidal neovascular membrane stratified by age of onset

Anatomical and visual outcomes of patients with active neovascular age related macular degeneration(nAMD) requiring monthly anti-VEGF treatment following switch to faricimab

Intravitreal Aflibercept for Diabetic Macular Oedema in Real-world; 5-Year Visual Acuity and Anatomical Outcomes

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Individualizing therapy for neovascular age-related macular degeneration with aflibercept (the VITAL study): A two year prospective, interventional single-centre trial

A Retrospective Study of Real World Data for stable wet AMD treatment with aflibercept

Treat-and-extend Aflibercept in the treatment of macular edema due to CRVO: 18 months results of real life data

Intravitreal Aflibercept for Diabetic Macular Oedema in Real-world; 24 Month Visual Acuity and Anatomical Outcomes

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Twelve Months Outcomes in Switched Patients Treated with Intravitreal Aflibercept for Diabetic Macular Oedema

Comparison of anatomical and functional outcomes of treatment with bevacizumab and ranibizumab injections in eyes with myopic choroidal neovascularization (mCNV)

Recurrence of Choroidal Neovascularization after cataract operation in Age Related Macular Degeneration

Characterizing posterior capsule rupture during cataract surgery in eyes with prior intravitreal injection

Three-Year Real World Outcomes of Aflibercept Treatment of Treatment-naïve Patients with Neovascular Age-related Macular Degeneration

To View More...

You must be signed into an individual account to use this feature.